$LGVN News

Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities

Longeveron Inc. Q1 2026 Earnings Call Summary

LGVN Set for Success in 2026

Longeveron (LGVN) Q1 2026 Earnings Transcript

Longeveron Q1 2026 Earnings Call: Complete Transcript

Longeveron Inc. (LGVN) Q1 2026 Earnings Call Transcript

Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update

Longeveron Q1 2026 Earnings Call: Complete Transcript

Longeveron Q1 EPS $(0.19) Misses $(0.16) Estimate, Sales $398.000K Beat $314.667K Estimate

Maxim Group Downgrades Longeveron to Hold

Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)

Longeveron Phase 2b HLHS Cell Therapy Trial Clears Final Safety Review; Top-Line Results Expected August 2026

Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron Reports FDA Type C Meeting On Laromestrocel In HLHS; Agency Rejects RVEF Endpoint, Requests Hard Clinical Outcomes, ELPIS II Phase 2b Top-Line Data Expected August 2026 With Potential BLA Path Discussed Post-Readout; FDA No Longer Refers To ELPIS II Trial As Pivotal

Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026

HC Wainwright & Co. Maintains Buy on Longeveron, Lowers Price Target to $8

Longeveron Files Prospectus Related To Resale Of 30.865M Shares By Selling Stockholder

Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

Longeveron Granted Chinese Patent For Potency Assay Methods For Assessing Human Mesenchymal Stem Cells

Longeveron (LGVN) Q4 2025 Earnings Call Transcript